Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Dec 19, 2018
Distillery Therapeutics

Neurology

BioCentury | Aug 17, 2018
Targets & Mechanisms

Unsaturated remyelination

Case Western spins out Convelo to develop remyelination drugs
BioCentury | Dec 1, 2016
Targets & Mechanisms

Not a peripheral story

Beyond peripheral autoimmunity in Type I diabetes
BioCentury | May 9, 2016
Emerging Company Profile

Deliver to the liver

How Topas is using the liver to induce systemic autoantigen tolerance
BioCentury | Sep 28, 2015
Company News

UCSD, PsychoGenics deal

BioCentury | Jan 19, 2015
Emerging Company Profile

Unlocking PADs

Padlock developing PAD inhibitors for autoimmune diseases
BioCentury | Dec 15, 2014
Clinical News

MyeloXen: Phase I/IIa ongoing

BioCentury | Oct 16, 2014
Translation in Brief

Translational tidbits

BioCentury | Oct 31, 2013
Targets & Mechanisms

Benztropine for MS

BioCentury | Sep 30, 2013
Clinical News

Endece preclinical data

Items per page:
1 - 10 of 153